ibrutinib plus venetoclax for first-line treatment of cll: 4-year follow-up data
Published 1 year ago • 466 plays • Length 1:56Download video MP4
Download video MP3
Similar videos
-
2:18
first-line ibrutinib and venetoclax in cll
-
2:43
outcomes in high-risk cll patients following fixed-duration treatment with ibrutinib plus venetoclax
-
1:53
achieving undetectable mrd with ibrutinib plus venetoclax for cll
-
1:23
captivate: fixed-duration ibrutinib plus venetoclax in patients with cll/sll
-
1:23
interim analysis of the flair study: efficacy of ibrutinib plus venetoclax in ighv unmutated cll
-
6:55
ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukaemia
-
2:39
the safety and efficacy of ibrutinib for the treatment of cll
-
1:43
eradic trial: preliminary results of mrd-guided ibrutinib plus venetoclax vs fcr
-
2:49
results from the phase iii echo trial of acalabrutinib plus br in mcl
-
3:28
the sympatico trial: ibrutinib plus venetoclax in tp53-mutated mcl
-
1:46
ruxolitinib in 2024 and beyond: the good, the suboptimal, and the failure
-
0:51
phase i study of copanlisib plus venetoclax in r/r dlbcl
-
2:45
optimizing the combination of ibrutinib plus venetoclax in cll
-
4:08
phase ib trial of ianalumab plus ibrutinib for cll
-
2:08
inotuzumab ozogamicin & venetoclax in the treatment of b-all: findings from a phase i trial
-
3:18
venetoclax and ibrutinib and drug combinations for cll
-
6:05
real-world data on the effect of ibrutinib flexible dosing treatment strategies on ttnt in cll/sll
-
2:27
ascembl: asciminib versus bosutinib in third-line treatment of cp-cml
-
1:02
a phase ii single-arm study of obinutuzumab plus ibrutinib as frontline treatment for fl and mzl
-
1:36
improve study update: safety and efficacy of venetoclax retreatment in r/r cll
-
1:36
obinutuzumab plus ibrutinib and venetoclax treatment continues to yield high response rates in cll
-
4:31
sequence of administration of ibrutinib with obinutuzumab in r/r cll patients